ANI Pharmaceuticals/ANIP

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of 116 products with a variety of indications and a robust portfolio of pipeline products. It has acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. The Company sources the raw materials for its products from both domestic and international suppliers.

Ticker

ANIP

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Nikhil Lalwani

Employees

642

Headquarters

Baudette, United States

ANIP Metrics

BasicAdvanced
$1.4B
Market cap
40.71
P/E ratio
$1.59
EPS
0.81
Beta
-
Dividend rate
$1.4B
0.81433
$70.81
$46.13
150K
3.949
3.117
59.689
59.868
17.69
3.67%
4.23%
7.97%
5.02%
40.71
2.629
3.014
5.387
13.198
44.26%
192.28%
32.67%

What the Analysts think about ANIP

Analyst Ratings

Majority rating from 5 analysts.
Buy

ANIP Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
13.24% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$137M
4.41%
Net income
$18M
1,554.55%
Profit margin
13.24%
1,495.18%

ANIP Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 21.49%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$1.28
$1.27
$1.00
$1.21
-
Expected
$0.68
$0.84
$0.86
$1.00
$0.96
Surprise
88.93%
50.59%
16.96%
21.49%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for ANI Pharmaceuticals stock?

ANI Pharmaceuticals (ANIP) has a market cap of $1.4B as of June 17, 2024.

What is the P/E ratio for ANI Pharmaceuticals stock?

The price to earnings (P/E) ratio for ANI Pharmaceuticals (ANIP) stock is 40.71 as of June 17, 2024.

Does ANI Pharmaceuticals stock pay dividends?

No, ANI Pharmaceuticals (ANIP) stock does not pay dividends to its shareholders as of June 17, 2024.

When is the next ANI Pharmaceuticals dividend payment date?

ANI Pharmaceuticals (ANIP) stock does not pay dividends to its shareholders.

What is the beta indicator for ANI Pharmaceuticals?

ANI Pharmaceuticals (ANIP) has a beta rating of 0.81. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the ANI Pharmaceuticals stock price target?

The target price for ANI Pharmaceuticals (ANIP) stock is $81.6, which is NaN% below the current price of $. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell ANI Pharmaceuticals stock

Buy or sell ANI Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing